On the stock market since 2022, it operates in the world of health and science. It has 4,980 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $174B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 24% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales fell about 5% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, SMDPY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SMDPY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.